Table 1—

General characteristics of study patients with bronchiectasis

Subjects n91
Mortality dead/alive27 (29.7)/64 (70.3)
Sex female/male53 (58.2)/38 (41.8)
Smoker current/former/never1 (1.1)/20 (22)/70 (76.9)
PSA/non-PSA20 (22)/71 (78)
Age in 1994 yrs51.7±12.1
Length of follow-up# months126.9±38.0
Period between CT and LF months13.0±14.1
CT criteria
 Bx extent33.1±21.0
 Dilatation severity39.7±24.8
 Wall thickness20.6±12.4
 Small airway plugging9.8±14.7
 Large airway plugging12.5±13.1
 Mosaicism7.5±10.2
 Emphysema3.9±8.0
LF criteria % pred
 FEV165.8±28.1
 FVC88.7±23.6
 FEV1/FVC83.1±9.0
 RV136.8±44.1
 TLC103.1±16.6
 RV/TLC126.9±31.3
TL,CO76.2±20.4
KCO95.4±22.1
Health-related quality of life questionnaire scores
 Fatigue4.7±2.4
 MRC wheeze+2.2±1.3
 MRC dyspnoea+2.2±1.0
 SGRQ total§45.9±18.1
 SGRQ symptoms§71.9±18.8
 SGRQ activities§49.1±24.5
 SGRQ impacts§35.7±19.0
Aetiology
 Idiopathic51 (56)
 Post infective20 (22)
 ABPA8 (8.8)
 PCD5 (5.5)
 Young’s syndrome4 (4.4)
 Hypogammaglobulinaemia3 (3.3)
  • Data are presented as n (%) or mean±sd, unless otherwise stated. Data are presented from time of entry into the cohort. PSA: Pseudomonas aeruginosa; CT: computed tomography; LF: lung function; Bx: bronchiectasis; % pred: % predicted; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; RV: residual volume; TLC: total lung capacity; TL,CO: transfer factor of the lung for carbon monoxide; KCO: transfer coefficient of the lung for carbon monoxide; MRC: Medical Research Council; SGRQ: St George’s Respiratory Questionnaire; ABPA: allergic bronchopulmonary aspergillosis; PCD: primary ciliary dyskinesia. #: from recruitment until March 1, 2007, or until patient died;: expressed as a percentage of the maximal possible score for each criterion; +: range 1–5, with a score of 1 representing greatest breathlessness on strenuous exercise; §: range 0–100, with a zero score indicating no impairment in quality of life.